MA39032A1 - Acide 4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë - Google Patents

Acide 4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë

Info

Publication number
MA39032A1
MA39032A1 MA39032A MA39032A MA39032A1 MA 39032 A1 MA39032 A1 MA 39032A1 MA 39032 A MA39032 A MA 39032A MA 39032 A MA39032 A MA 39032A MA 39032 A1 MA39032 A1 MA 39032A1
Authority
MA
Morocco
Prior art keywords
phenoxy
oxazolo
pyrimidin
chloro
dimethyl
Prior art date
Application number
MA39032A
Other languages
English (en)
Other versions
MA39032B2 (fr
Inventor
Philip Janiak
Bruno Poirier
Véronique Briand
Sabine Gratzer
Thomas Huebschle
Dieter Kadereit
Ashfaq Parkar
Matthias Schaefer
Paulus Wohlfart
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49488539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39032(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA39032A1 publication Critical patent/MA39032A1/fr
Publication of MA39032B2 publication Critical patent/MA39032B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne de l'acide {4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique ou un sel pharmaceutiquement acceptable de celui-ci destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë) (ira). L'invention porte également sur un médicament et une composition pharmaceutique de celui-ci.
MA39032A 2013-10-15 2014-10-15 Acide 4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë MA39032B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20130306417 EP2862574A1 (fr) 2013-10-15 2013-10-15 Acide {4-[5-(3-chloro-phénoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-diméthyl-phénoxy}-acétique pour son utilisation dans la prévention ou le traitement de l'insuffisance rénale aiguë
PCT/EP2014/072078 WO2015055694A1 (fr) 2013-10-15 2014-10-15 Acide 4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë

Publications (2)

Publication Number Publication Date
MA39032A1 true MA39032A1 (fr) 2017-04-28
MA39032B2 MA39032B2 (fr) 2020-10-28

Family

ID=49488539

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39032A MA39032B2 (fr) 2013-10-15 2014-10-15 Acide 4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë

Country Status (24)

Country Link
US (1) US9782411B2 (fr)
EP (2) EP2862574A1 (fr)
JP (1) JP6458016B2 (fr)
KR (1) KR102348608B1 (fr)
CN (1) CN105658220B (fr)
AR (1) AR098028A1 (fr)
AU (1) AU2014336254B9 (fr)
BR (1) BR112016007669B1 (fr)
CA (1) CA2926211C (fr)
CL (1) CL2016000724A1 (fr)
CR (1) CR20160172A (fr)
DK (1) DK3057591T3 (fr)
EA (1) EA032012B1 (fr)
ES (1) ES2898403T3 (fr)
FI (1) FI3057591T3 (fr)
IL (2) IL244686B (fr)
MA (1) MA39032B2 (fr)
MX (1) MX383252B (fr)
PH (1) PH12016500563A1 (fr)
PT (1) PT3057591T (fr)
SG (1) SG11201602263TA (fr)
TN (1) TN2016000110A1 (fr)
TW (1) TWI685340B (fr)
WO (1) WO2015055694A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2859487T3 (es) * 2016-10-05 2021-10-04 Mitobridge Inc Métodos para tratar las lesiones renales agudas
CN106905348B (zh) * 2017-02-13 2018-12-04 牡丹江医学院 一种预防和治疗急性肾损伤的药物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10033353A1 (de) 2000-07-08 2002-01-24 Aventis Pharma Gmbh Breit einsetzbares Verfahren zur Identifizierung von Modulatoren von G-Protein gekoppelten Rezeptoren
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
USRE43728E1 (en) 2003-11-21 2012-10-09 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
PT2523962E (pt) * 2010-01-14 2014-02-06 Sanofi Sa Derivados de ácidos carboxílicos com um anel oxazolopirimidina substituído em 2,5

Also Published As

Publication number Publication date
BR112016007669B1 (pt) 2023-01-10
KR20160060759A (ko) 2016-05-30
AR098028A1 (es) 2016-04-27
CR20160172A (es) 2016-06-08
HK1225611A1 (zh) 2017-09-15
FI3057591T3 (fi) 2024-10-08
KR102348608B1 (ko) 2022-01-06
CA2926211A1 (fr) 2015-04-23
JP2016534986A (ja) 2016-11-10
US9782411B2 (en) 2017-10-10
JP6458016B2 (ja) 2019-01-23
US20160235756A1 (en) 2016-08-18
WO2015055694A1 (fr) 2015-04-23
IL282097A (en) 2021-05-31
MA39032B2 (fr) 2020-10-28
AU2014336254B9 (en) 2020-02-20
IL244686A0 (en) 2016-04-21
EP3057591B1 (fr) 2021-09-08
IL244686B (en) 2021-04-29
AU2014336254B2 (en) 2020-02-06
CN105658220B (zh) 2019-04-19
CA2926211C (fr) 2022-03-29
EA032012B1 (ru) 2019-03-29
SG11201602263TA (en) 2016-04-28
PH12016500563A1 (en) 2016-05-23
TN2016000110A1 (en) 2017-07-05
TWI685340B (zh) 2020-02-21
TW201605453A (zh) 2016-02-16
MX383252B (es) 2025-03-13
BR112016007669A2 (pt) 2017-08-01
CL2016000724A1 (es) 2016-09-23
NZ719089A (en) 2020-09-25
ES2898403T3 (es) 2022-03-07
CN105658220A (zh) 2016-06-08
EP2862574A1 (fr) 2015-04-22
EP3057591A1 (fr) 2016-08-24
PT3057591T (pt) 2021-12-09
EA201690762A1 (ru) 2016-07-29
DK3057591T3 (da) 2021-12-13
MX2016004778A (es) 2017-01-11

Similar Documents

Publication Publication Date Title
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
MA42287B1 (fr) Traitement de patients atteints de diabète sucré de type 2
MX388825B (es) Uso y dosificacion de agentes terapeuticos para endometriosis.
BR112019025578A2 (pt) Mesembrenol e/ou mesembranol para profilaxia e tratamento de pacientes que sofrem de epilepsia e doenças associadas
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MX393629B (es) Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma.
MA39032A1 (fr) Acide 4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë
MA35636B1 (fr) Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide
MA39175A1 (fr) Capsule comprend 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-(6-(4-(4-ethyl-piperazin-1-yl)-phenylamino)-pyrimidin-4-yl)-1-methyl-uree, liant et desintegrant, pour le traitement des maladies proliferatives
MA50383B1 (fr) Agents thérapeutiques pour l'utilisation dans le traitement du syndrome des jambes sans repos
MA45639B1 (fr) Combinaison d'antagonistes purs du récepteur 5-ht6 avec des inhibiteurs d'acétylcholinestérase
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA39833A (fr) Nouvelle utilisation du n,n-bis-2-mercaptoéthyl isophtalamide
MA35850B1 (fr) Nouvelle utilisation thérapeutique d'antagonistes du récepteur p75
EA201391827A1 (ru) Соединения [1,2,4]тиадиазин 1,1-диоксида для снижения мочевой кислоты в сыворотке
FR2992863A1 (fr) Composition pharmaceutique pour le traitement du cancer
MA44850A (fr) Composition ophtalmique comprenant une combinaison synergique de glycogène et d'acide hyaluronique ou d'un sel de celui-ci
Teraoka et al. Effects of long-term administration with generic benzbromarone on serum uric acid level and liver function in hyperuricemia patients
BR112016007588A2 (pt) formas de dosagem farmacêutica compreendendo sódio 1-[6- (morfolina-4-il) pirimidina-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato
EA202091903A1 (ru) Кристаллическая форма битегравир-натрия